Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology, University of Sao Paulo School of Medicine, São Paulo, Brazil.
Faculty of Psychology, Universidad Autónoma de Madrid, Madrid, Spain.
Infect Dis Ther. 2016 Mar;5(1):53-64. doi: 10.1007/s40121-015-0101-y. Epub 2016 Jan 13.
Evidence shows that treatment for hepatitis B virus (HBV) can suppress viral load. Among the factors directly linked to therapeutic success is adherence to the treatment. Several instruments to assess adherence are available, but they are not validated for use in chronic hepatitis B. The purpose of this paper was to adapt and validate the "Assessment of Adherence to Antiretroviral Therapy Questionnaire-HIV" (CEAT-VIH) for patients with chronic hepatitis B (referred to herein as CEAT-HBV).
The validity of the adapted questionnaire evidence was established through concurrent, criterion, and construct validities.
We found negative and significant correlation between the domain "degree of compliance to antiviral therapy" assessed by CEAT-HBV and the Morisky test (r = -0.62, P < 0.001) and between the domain "barriers to adherence" and HBV viral load (r = -0.42, P < 0.001). In terms of the construct's discriminative capacity, scores greater than or equal to 80 detected antiviral therapy success, which are necessary for the prediction of an undetectable HBV viral load. Thus, a cutoff value of 80.5 was set with a value of 81% for sensitivity and 67% for specificity.
The CEAT-HBV identified 43% (n = 79) non-adherent patients and was shown to be a useful tool in clinical practice.
有证据表明，乙型肝炎病毒（HBV）的治疗可以抑制病毒载量。与治疗成功直接相关的因素之一是对治疗的依从性。有几种评估依从性的工具，但它们未经验证可用于慢性乙型肝炎。本文旨在改编和验证“抗逆转录病毒治疗依从性评估问卷 - HIV”（CEAT-VIH），用于慢性乙型肝炎患者（以下简称 CEAT-HBV）。
通过同时、标准和结构有效性来确定改编问卷证据的有效性。
我们发现，CEAT-HBV 评估的“抗病毒治疗依从性程度”与 Morisky 测试呈负显著相关（r = -0.62，P < 0.001），“依从性障碍”与 HBV 病毒载量呈负相关（r = -0.42，P < 0.001）。就结构的区分能力而言，得分大于或等于 80 分可检测出抗病毒治疗的成功，这是预测 HBV 病毒载量不可检测所必需的。因此，设定了 80.5 的截止值，灵敏度为 81%，特异性为 67%。
CEAT-HBV 确定了 43%（n = 79）不依从的患者，并且在临床实践中是一种有用的工具。
Zotero 插件